Nephros, Inc.

Equities

NEPH

US6406714005

Environmental Services & Equipment

Market Closed - Nasdaq 04:30:00 2024-04-17 pm EDT 5-day change 1st Jan Change
1.99 USD -1.97% Intraday chart for Nephros, Inc. -6.13% -42.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Nephros, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Nephros, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Nephros, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (NEPH) NEPHROS Posts Q3 Revenue $3.7M, vs. Street Est of $3.37M MT
Nephros, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nephros, Inc., Hires Judy Krandel as Chief Financial Officer CI
Earnings Flash (NEPH) NEPHROS Posts Q2 Revenue $3.5M, vs. Street Est of $3.1M MT
Transcript : Nephros, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Nephros, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Nephros, Inc., Q1 2023 Earnings Call, May 10, 2023
Nephros, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nephros, Inc. Announces Management Changes CI
Nephros, Inc. Announces CEO Changes CI
Nephros, Inc. Announces Preliminary Revenue Results for the First Quarter Ended March 31, 2023 CI
Transcript : Nephros, Inc., Q4 2022 Earnings Call, Mar 08, 2023
Nephros, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nephros, Inc. and Donastar Enterprises Llc Announce Strategic Partnership CI
Nephros, Inc. Announces Board Changes CI
Nephros, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2022 CI
Blue Water Solutions, Inc. completed the acquisition of Substantially all of Pathogen Detection Systems Business of Nephros, Inc.. CI
Transcript : Nephros, Inc., Q3 2022 Earnings Call, Nov 02, 2022
Nephros, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022 CI
B. Riley Securities Lowers Nephros' Price Target to $4.25 from $5.25 Ahead of Q3 Results, Lowers Estimates; Maintains Buy Rating MT
Nephros to Sell Pathogen Detection Systems Business MT
Nephros, Inc. Provides Revenue Guidance for the Quarter Ended September 30, 2022 CI
Chart Nephros, Inc.
More charts
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. It operates through the Water Filtration segment. In the medical markets, it sells water filtration products. In the commercial markets, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Its products are marketed primarily to the food service, hospitality, convenience store, and health care markets. These commercial products are also marketed into medical markets, as supplemental filtration to its medical filters. The Company’s filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.99 USD
Average target price
4.75 USD
Spread / Average Target
+138.69%
Consensus
  1. Stock Market
  2. Equities
  3. NEPH Stock
  4. News Nephros, Inc.
  5. B. Riley Securities Lowers Nephros' Price Target to $4.25 from $5.25 Ahead of Q3 Results, Lowers Estimates; Maintains Buy Rating